ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1030

Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis

Yeo jin lee1, Eun-Ju Lee2, Soo Min Ahn2, Seokchan Hong2, Ji Seon Oh3, Chang Keun Lee2, Bin Yoo2 and Yong Gil Kim2, 1Asan medical center, Seoul, Republic of Korea, 2Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 3Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Ankylosing spondylitis (AS) has been known to have auto-inflammatory nature, hence, the efficacy of autoantibodies is low. However, studies on autoantibodies are ongoing, with some studies showing associations. Previous studies showed that anti-PPM1A IgG was increased in patients with AS and associated with radiographic progression (ref: JS Lee et al. 2020 JCM). However, the diagnostic usefulness was limited due to relatively low sensitivity and specificity (ref: YG Kim et al. 2014 ANR). Therefore, this study aimed to evaluate the usefulness of anti-PPM1A-IgM rather than IgG in patients with active AS before anti-TNF agent administration compared with those with active rheumatoid arthritis (RA).

Methods: Serum samples were obtained from the registry cohort in a single-tertiary center in Korea. The serum levels of Anti-PPM1A-IgG/IgM were measured by direct sandwich enzyme-linked immunosorbent assay. Electronic medical records including laboratory data, Bath AS Disease Activity Index (BASDAI), and radiographic findings were reviewed. Receiver operating characteristic (ROC) analysis was used for the prediction of diagnostic sensitivity and specificity.

Results: Samples were collected from 16 healthy controls (HC), 28 patients diagnosed with AS, and 28 patients with RA. Anti-PPM1A-IgM was significantly lower in the AS group than that in other groups (0.39 vs. 0.62 in RA vs. 1.12 in HC, p=0.000). Among 28 patients with AS, high grade sacroiliitis (grade 3 or 4) was seen in 20 patients and HLA-B27 positivity in 27 patients; the median BASDAI was 6.00 (interquartile range, 5.35–6.80). Regarding the diagnostic usefulness of AS compared with that of RA, the area under the curve (AUC) of anti-PPM1A IgM was 0.839 (p=0.000, sensitivity 78.6%, specificity 71.4%) and of C-reactive protein (CRP) was 0.805 (p=0.000, sensitivity 64.3%, specificity 89.3%). However, anti-PPM1A-IgG and erythrocyte sedimentation rate did not show significance. When ROC analysis was performed using both CRP and anti-PPM1A-IgM, a sensitivity of 75% and specificity of 96.4% were identified with an AUC of 0.921.

Conclusion:
In conclusion, decreased level of anti-PPM1A-IgM implies high diagnostic utility in patients with active AS. Thus, when sacroiliitis cannot be checked, CRP and anti-PPM1A-IgM measurements can be used in the diagnosis of AS with differentiation from active RA.

Reference:
J Clin Med. 2020;9(12):3968
Arthritis Rheumatol. 2014;66(10):2793-2803

Supporting image 1


Disclosures: Y. lee, None; E. Lee, None; S. Ahn, None; S. Hong, None; J. Oh, None; C. Lee, None; B. Yoo, None; Y. Kim, None.

To cite this abstract in AMA style:

lee Y, Lee E, Ahn S, Hong S, Oh J, Lee C, Yoo B, Kim Y. Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/diagnostic-usefulness-of-anti-ppm1a-igm-in-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-usefulness-of-anti-ppm1a-igm-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology